HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy

Hepatocellular carcinoma (HCC) is a major cause of cancer mortality worldwide and available therapies, including immunotherapies, are ineffective for many patients. HCC is characterized by intratumoral hypoxia, and increased expression of hypoxia-inducible factor 1α (HIF-1α) in diagnostic biopsies i...

Descripción completa

Detalles Bibliográficos
Autores principales: Salman, Shaima, Meyers, David J., Wicks, Elizabeth E., Lee, Sophia N., Datan, Emmanuel, Thomas, Aline M., Anders, Nicole M., Hwang, Yousang, Lyu, Yajing, Yang, Yongkang, Jackson, Walter, Dordai, Dominic, Rudek, Michelle A., Semenza, Gregg L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057582/
https://www.ncbi.nlm.nih.gov/pubmed/35499076
http://dx.doi.org/10.1172/JCI156774

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057582/
https://www.ncbi.nlm.nih.gov/pubmed/35499076
http://dx.doi.org/10.1172/JCI156774

Ejemplares similares